{"id":52358,"date":"2022-12-27T16:02:06","date_gmt":"2022-12-27T15:02:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/6-87-billion-worldwide-in-vivo-cro-industry-to-2027-players-include-charles-river-laboratories-international-evotec-icon-and-iris-pharma-researchandmarkets-com\/"},"modified":"2022-12-27T16:02:06","modified_gmt":"2022-12-27T15:02:06","slug":"6-87-billion-worldwide-in-vivo-cro-industry-to-2027-players-include-charles-river-laboratories-international-evotec-icon-and-iris-pharma-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/6-87-billion-worldwide-in-vivo-cro-industry-to-2027-players-include-charles-river-laboratories-international-evotec-icon-and-iris-pharma-researchandmarkets-com\/","title":{"rendered":"$6.87 Billion Worldwide In-vivo CRO Industry to 2027: Players Include Charles River Laboratories International, Evotec, ICON and Iris Pharma – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “In-vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global in-vivo CRO market size reached US$ 4.2 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 6.87 Billion by 2027, exhibiting a CAGR of 8.55% during 2021-2027.\n<\/p>\n

\nKeeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.\n<\/p>\n

\nIn-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual basis. They support pharmaceutical and biotechnology companies in formulating effective drugs, vaccines, and medical devices by providing outsourcing services.\n<\/p>\n

\nAs compared to in-vitro CRO, in-vivo CRO deals with the research performed within the living organism and conducts human clinical trials to assess the safety and efficacy of the drugs instead of organizing examinations on removed cells and tissues. They aid research institutions in managing complex medical testing, developing effective medications at minimal costs, and optimizing workflow by avoiding delays caused by hiring, fundraising, and clinical preparations.\n<\/p>\n

\nAs a result, in-vivo CRO finds extensive application in pain management, oncology, and treating central nervous system (CNS) injuries and other disorders. Currently, they are bifurcated into rodent- and non-rodent-based types.\n<\/p>\n

\nIncreasing prevalence of various cardiovascular ailments, especially amongst the geriatric population, and the growing need for effective medications and novel oncology-based therapies for diagnosis and treatment are primarily driving the market growth.\n<\/p>\n

\nAdditionally, the rising demand for clinical-scale manufacturing of active pharmaceutical ingredients (APIs) by contract research, development, and manufacturing organizations (CRDMOs) and the shifting inclination toward biosimilars over format monoclonal antibodies are acting as other growth-inducing factors.\n<\/p>\n

\nFurthermore, the fueling health concerns have prompted biotechnology companies to engineer effective novel vaccines in collaboration with CRO, especially during the COVID-19 pandemic, which is contributing to the market growth.\n<\/p>\n

\nMoreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth. Apart from this, the advent of bioequivalence, rapid growth in generics, ongoing patent expirations, and continuous research and development (R&D) activities to engineer personalized medicines are creating a positive outlook for the market.\n<\/p>\n

\nCompanies Mentioned<\/strong>\n<\/p>\n